Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events

Subsequent Events	3 Months Ended
Mar. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	17. Subsequent Events On May 3, 2023, an additional 60,000,000 ordinary shares of $0.01 par value each were authorized by the shareholders at our 2023 Annual General Meeting of Shareholders (2023 Annual Meeting). In addition, we asked our shareholders to renew the authorization of our board of directors to issue shares and the disapplication of statutory preemption rights at our 2023 Annual Meeting, and to extend that authorization to the increase in authorized share capital that was approved. Our shareholders renewed the authorization of our board of directors to issue shares; however, although we received over 61% support of the votes cast on renewing the pre-emption rights opt-out authority, we did not receive the affirmative vote of at least 75% of the votes cast as required under Irish law for the passing of special resolutions.

Subsequent Events

3 Months Ended

Mar. 31, 2023

17. Subsequent Events

On May 3, 2023, an additional 60,000,000 ordinary shares of $0.01 par value each were authorized by the shareholders at our 2023 Annual General Meeting of Shareholders (2023 Annual Meeting). In addition, we asked our shareholders to renew the authorization of our board of directors to issue shares and the disapplication of statutory preemption rights at our 2023 Annual Meeting, and to extend that authorization to the increase in authorized share capital that was approved. Our shareholders renewed the authorization of our board of directors to issue shares; however, although we received over 61% support of the votes cast on renewing the pre-emption rights opt-out authority, we did not receive the affirmative vote of at least 75% of the votes cast as required under Irish law for the passing of special resolutions.